Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion type Assertion NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_head.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion description "[The TTP pathway of TNF-alpha and GM-CSF mRNA degradation is a possible novel target for anti-TNF-alpha therapies for rheumatoid arthritis, and also for other conditions proven to respond to anti-TNF-alpha therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_provenance.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion evidence source_evidence_literature NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_provenance.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion SIO_000772 15535838 NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_provenance.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion wasDerivedFrom befree-20140225 NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_provenance.
- NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_assertion wasGeneratedBy ECO_0000203 NP882101.RAPOSyzjaAORiiWQ0iwweR_QAYJVTbRcqNBg54W8TeKjc130_provenance.